SteinCares will handle all regulatory filings, registrations and commercialisation of Ranibizumab in LATAM
 
Lupin has entered into a license and supply agreement with SteinCares, a leading speciality healthcare company in Latin America, for the commercialisation of Lupin’s biosimilar ranibizumab across Latin America excluding Mexico and Argentina.
 
Under the terms of the agreement, SteinCares will handle all regulatory filings, registrations and commercialisation of Ranibizumab in LATAM, while Lupin will be responsible for manufacturing the same.
 
Ranibizumab is a recombinant humanised IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A). Its indications encompass the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Diabetic Retinopathy (DR) and Myopic Choroidal Neovascularization (mCNV).
 
Dr Cyrus Karkaria, President Biotechnology, Lupin said, “Our partnership with SteinCares underscores our commitment to providing innovative, high-quality healthcare solutions to patients in LATAM. We intend to transform the landscape of retinal care in Latin America, ensuring access to advanced therapies that improve the quality of life of patients.”
 
“This partnership with Lupin strengthens our portfolio and further reinforces SteinCares’ position as a biosimilar powerhouse in Latin America. We have consistently been the first to market products from highly regulated markets across several countries in the region. Our presence has translated into significant cost savings for healthcare institutions, driven by decades of experience and a deep understanding of Latin America's healthcare landscape,” said Sebastián Katz, Chief Strategy Officer, SteinCares.